Virpax Pharmaceuticals, INC 8-K filings

Virpax Pharmaceuticals announces Nasdaq delisting due to non-compliance with equity requirements, along with multiple board and executive resignations.

Virpax Pharmaceuticals is set to be delisted from the Nasdaq due to non-compliance with minimum stockholders' equity requirements, accompanied by the resignation of key board members and the CFO.

Virpax Pharmaceuticals enacted a 1-for-25 reverse stock split of its common stock, effective March 21, 2025.

Virpax Pharmaceuticals appoints Charn Deol as an independent director, filling the vacancy left by Jaydriane Panis' resignation.

Jaydriane Panis resigns from Virpax Pharmaceuticals' Board of Directors and associated committees due to compliance requirements with his employer, effective immediately.

Virpax Pharmaceuticals has announced a $6 million public offering of common stock and pre-funded warrants to fund clinical trials, marketing, and general corporate purposes.

Virpax Pharmaceuticals held a special meeting on January 15, 2025, where stockholders approved a reverse stock split and elected five directors, but did not approve the adjournment of the meeting.

Virpax Pharmaceuticals has received an extension from Nasdaq to regain compliance with listing rules, contingent on meeting certain financial and operational milestones by April 1, 2025.

Virpax Pharmaceuticals amended independent contractor agreements with its CEO and CFO to clarify that their services are provided through their respective consulting corporations.

Virpax Pharmaceuticals has appointed Jay Panis, a seasoned financial professional, to its Board of Directors following the resignation of Gary Herman.

Gary Herman has resigned from the Virpax Pharmaceuticals Board of Directors and all related committees, effective immediately.

Virpax Pharmaceuticals has amended its bylaws to lower the quorum requirement for shareholder meetings from a majority to 34% of voting power.

Virpax Pharmaceuticals has regained compliance with Nasdaq listing rules regarding independent directors and audit committee composition following the appointment of a new independent director.

Virpax Pharmaceuticals has regained compliance with Nasdaq listing rules, appointed a new independent director, and announced progress in its drug development programs.

Virpax Pharmaceuticals has appointed Usama Chaudhry as its new Chief Financial Officer, effective November 18, 2024.

Virpax Pharmaceuticals has successfully closed a $5 million public offering of common stock and pre-funded warrants to support the development of its pain management technologies.

Virpax Pharmaceuticals is facing significant challenges including director resignations, a Nasdaq delisting notice, and allegations of improper board actions.

Virpax Pharmaceuticals received a Nasdaq deficiency notice for its stock price falling below $1.00 and saw the immediate resignation of its CEO and CFO due to disagreements with the board.

Virpax Pharmaceuticals has received a delisting notice from Nasdaq after failing to meet the minimum stockholders' equity requirement, and intends to appeal the decision.

Virpax Pharmaceuticals has appointed board member Katharyn Field as Vice President and principal executive officer, effective immediately.

Virpax Pharmaceuticals has extended the deadline for a potential $5 million financing agreement with Corbo Capital to November 30, 2024, with a possible 30-day extension, and board resignations are tied to the funding.

Virpax Pharmaceuticals experienced significant changes with the resignation of its auditor, EisnerAmper LLP, and the immediate departure of Board Chairman Eric Floyd due to disagreements over company policies.

Virpax Pharmaceuticals announces the immediate resignation of board member Vanila M. Singh, MD, effective September 16, 2024.

Virpax Pharmaceuticals announced its second quarter 2024 financial results, highlighted by progress in its drug development programs and recent financing activities.

Virpax Pharmaceuticals received a Nasdaq extension to regain compliance and stockholders approved amendments to the 2022 Equity Incentive Plan at the annual meeting.

Virpax Pharmaceuticals has fully prepaid a $2.525 million secured promissory note, including principal and accrued interest, ahead of its maturity date.

Virpax Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock maintained a price of $1.00 or more for ten consecutive business days.

Virpax Pharmaceuticals issued 1,975,283 shares of common stock to investors who exercised warrants, resulting in approximately $2.67 million in proceeds.

Virpax Pharmaceuticals reports positive results from a swine model pilot study of Probudur, its long-acting pain relief formulation, showing good tolerability and a slow-release profile.

Virpax Pharmaceuticals has obtained a $2.5 million secured loan, finalized a litigation settlement, and appointed four new board members while five existing members resigned.